CAS 1092939-17-7: Jakafi
Description:Jakafi, known generically as ruxolitinib, is a selective inhibitor of Janus kinases (JAK1 and JAK2) and is primarily used in the treatment of certain myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis. It functions by modulating the immune response and reducing inflammation by inhibiting the signaling pathways of various cytokines. Ruxolitinib is administered orally and is characterized by its ability to improve symptoms related to these conditions, such as splenomegaly and constitutional symptoms. The substance has a molecular formula that reflects its complex structure, which includes a pyrrolo[2,3-d]pyrimidine core. Its pharmacokinetics indicate a moderate bioavailability, with metabolism primarily occurring in the liver via cytochrome P450 enzymes. Common side effects may include anemia, thrombocytopenia, and increased risk of infections due to its immunosuppressive properties. Overall, Jakafi represents a significant advancement in targeted therapies for hematological disorders.
Formula:C17H18N6·H3O4P
InChI:InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
InChI key:InChIKey=JFMWPOCYMYGEDM-XFULWGLBSA-N
SMILES:N#CCC(N1N=CC(=C1)C=2N=CN=C3NC=CC32)C4CCCC4.O=P(O)(O)O
- Synonyms:
- (Betar)-Beta-Cyclopentyl-4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazole-1-Propanenitrile
- 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-, phosphate (1:1)
- INC 424 phosphate
- INCB 018424 phosphate
- Incb-018424
- Jakafi
- Jakavi
- R-Incb018424
- R-Ruxolitinib
- Ruxolitinib (INCB 018424)
- See more synonyms
- Ruxolitinib phosphate
- Ruxolitinib phosphate salt